# PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

Study · id `cardio:ct-nct05709626` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05709626](<https://clinicaltrials.gov/study/NCT05709626>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT05709626

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2268 participants.

## Technical summary

Registry record NCT05709626. Randomized; no masking; primary purpose treatment. Start 2023-04-07 (actual); primary completion 2026-02-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2268 participants (enrolled count; ClinicalTrials.gov record NCT05709626, source copy `cardio:ctgov-nct05709626-2026-11-09`, retrieved 2026-11-18)
- Started: 2023-04-07 (actual) (ClinicalTrials.gov record NCT05709626, source copy `cardio:ctgov-nct05709626-2026-11-09`, retrieved 2026-11-18)
- Primary completion: 2026-02-12 (actual) (ClinicalTrials.gov record NCT05709626, source copy `cardio:ctgov-nct05709626-2026-11-09`, retrieved 2026-11-18)
- Completion: 2026-04-27 (actual) (ClinicalTrials.gov record NCT05709626, source copy `cardio:ctgov-nct05709626-2026-11-09`, retrieved 2026-11-18)
- Countries: Japan (ClinicalTrials.gov record NCT05709626, source copy `cardio:ctgov-nct05709626-2026-11-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05709626-2026-11-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
- Acronym: PREMIUM
- Condition: ST-segment Elevation Myocardial Infarction (STEMI)
- Intervention (Drug): No aspirin (Prasugurel monotherapy)
- Intervention (Drug): 12-month DAPT
- Lead sponsor: Kindai University
- Lead sponsor class: OTHER
- Collaborator: Boston Scientific Corporation
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as a collaborator: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: ad4f335de7285eb81784be1b666d49e44e9681b0facb33fa8fe6c025cbce9eb6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
